인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
DBpia AI
AI 에이전트
AI 아이디어
AI 리더
AI 뷰어
Citeasy
크롬 서지관리 다운로드
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록·키워드
ABSTRACT Background The management of moderate to severe hidradenitis suppurativa (HS) is complex with secondary failure of monoclonal antibodies frequent. Real‐world evidence regarding the treatment landscape before starting biologic therapy has been well‐documented, however, the role of switching between biologic agents is less well‐described. Objectives We aimed to describe real‐world data regarding the use of biologics and small‐molecule inhibitors in patients with HS. Methods Data from the TriNETX platform a deidentified global database of over 330 million patients from healthcare networks and institutions was queried. Results A total of 214,229 patients with a diagnosis of HS were identified, of whom 15,689 had exposure to the biologic and small molecule therapies listed (7.32%). Of this biologic and small molecule therapy‐experienced cohort, the average age was 41.8 years with 72.8% cohort being female. Patients had median follow‐up time of 1014 days (IQR = 1916 days). Of the 15,689 patients included, 919 progressed to a second‐line agent (5.9%). The longest median time on first‐line treatment was Certolizumab at 715 days ( n = 141 patients) and the shortest was for Secukinumab at 180 days ( n = 1745 patients). The most prevalent second‐line therapies were ‘Other’ nonbiologic therapies ( n = 476, 51.8%) followed by infliximab ( n = 91, 9.8%), adalimumab ( n = 187, 20.3%) and secukinumab ( n = 134, 14.6%). Conclusions The highest rates of long‐term single treatment persistence were seen in secukinumab (90.3%), upadacitinib (89.1%) and adalimumab (82.5%).
인공지능 문자 인식 모델을 통해 추출된 텍스트로, 일부 오타나 오류가 포함될 수 있으나 지속적으로 개선 중입니다.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
최근 본 자료 전체보기
